Adult obesity prevalence: female (age-standardized, %) vs Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) in Costa Rica
In 2024, adult obesity prevalence: female (age-standardized, %) in Costa Rica stood at 39.4%, against 87% for measles-containing-vaccine second-dose (MCV2) immunization coverage (%).
Change the pair
Compare different indicators
The series
Over time
Costa Rica, spaced by time. Both series are in %, so they share one axis; the legend names each line.
Adult obesity prevalence: female (age-standardized, %) and Measles-containing-vaccine second-dose (MCV2) immunization coverage (%)
Unit: % · 56 observations
Estimates are listed as such in the table below No figure published for these periods
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Adult obesity prevalence: female (age-standardized, %) | 2024 | Estimate | 39.4% |
| Adult obesity prevalence: female (age-standardized, %) | 2023 | Estimate | 38.6% |
| Adult obesity prevalence: female (age-standardized, %) | 2022 | Estimate | 37.8% |
| Adult obesity prevalence: female (age-standardized, %) | 2021 | Estimate | 37% |
| Adult obesity prevalence: female (age-standardized, %) | 2020 | Estimate | 36.2% |
| Adult obesity prevalence: female (age-standardized, %) | 2019 | Estimate | 35.4% |
| Adult obesity prevalence: female (age-standardized, %) | 2017 | Estimate | 33.8% |
| Adult obesity prevalence: female (age-standardized, %) | 2016 | Estimate | 33% |
| Adult obesity prevalence: female (age-standardized, %) | 2015 | Estimate | 32.1% |
| Adult obesity prevalence: female (age-standardized, %) | 2014 | Estimate | 31.3% |
| Adult obesity prevalence: female (age-standardized, %) | 2013 | Estimate | 30.4% |
| Adult obesity prevalence: female (age-standardized, %) | 2012 | Estimate | 29.6% |
| Adult obesity prevalence: female (age-standardized, %) | 2011 | Estimate | 28.7% |
| Adult obesity prevalence: female (age-standardized, %) | 2010 | Estimate | 27.9% |
| Adult obesity prevalence: female (age-standardized, %) | 2009 | Estimate | 27% |
| Adult obesity prevalence: female (age-standardized, %) | 2007 | Estimate | 25.4% |
| Adult obesity prevalence: female (age-standardized, %) | 2006 | Estimate | 24.7% |
| Adult obesity prevalence: female (age-standardized, %) | 2005 | Estimate | 24% |
| Adult obesity prevalence: female (age-standardized, %) | 2003 | Estimate | 22.5% |
| Adult obesity prevalence: female (age-standardized, %) | 2002 | Estimate | 21.8% |
| Adult obesity prevalence: female (age-standardized, %) | 2000 | Estimate | 20.3% |
| Adult obesity prevalence: female (age-standardized, %) | 1999 | Estimate | 19.5% |
| Adult obesity prevalence: female (age-standardized, %) | 1998 | Estimate | 18.8% |
| Adult obesity prevalence: female (age-standardized, %) | 1997 | Estimate | 18% |
| Adult obesity prevalence: female (age-standardized, %) | 1996 | Estimate | 17.3% |
| Adult obesity prevalence: female (age-standardized, %) | 1995 | Estimate | 16.6% |
| Adult obesity prevalence: female (age-standardized, %) | 1994 | Estimate | 15.9% |
| Adult obesity prevalence: female (age-standardized, %) | 1993 | Estimate | 15.2% |
| Adult obesity prevalence: female (age-standardized, %) | 1991 | Estimate | 13.9% |
| Adult obesity prevalence: female (age-standardized, %) | 1990 | Estimate | 13.3% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2025 | Estimate | 92% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2024 | Estimate | 87% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2023 | Estimate | 83% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2022 | Estimate | 75% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2021 | Estimate | 69% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2020 | Estimate | 81% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2019 | Estimate | 93% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2018 | Estimate | 93% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2017 | Estimate | 93% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2016 | Estimate | 87% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2015 | Estimate | 90% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2014 | Estimate | 90% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2013 | Estimate | 92% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2012 | Estimate | 95% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2011 | Estimate | 80% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2010 | Estimate | 79% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2009 | Estimate | 84% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2008 | Estimate | 89% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2007 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2006 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2005 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2004 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2003 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2002 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2001 | Estimate | 0% |
| Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) | 2000 | Estimate | 0% |
Shared periods
Side by side
21 periods are published for both series in Costa Rica as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Adult obesity prevalence: female (age-standardized, %) | Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) |
|---|---|---|
| 2000 | 20.3% WHO | 0% WHO |
| 2002 | 21.8% WHO | 0% WHO |
| 2003 | 22.5% WHO | 0% WHO |
| 2005 | 24% WHO | 0% WHO |
| 2006 | 24.7% WHO | 0% WHO |
| 2007 | 25.4% WHO | 0% WHO |
| 2009 | 27% WHO | 84% WHO |
| 2010 | 27.9% WHO | 79% WHO |
| 2011 | 28.7% WHO | 80% WHO |
| 2012 | 29.6% WHO | 95% WHO |
| 2013 | 30.4% WHO | 92% WHO |
| 2014 | 31.3% WHO | 90% WHO |
| 2015 | 32.1% WHO | 90% WHO |
| 2016 | 33% WHO | 87% WHO |
| 2017 | 33.8% WHO | 93% WHO |
| 2019 | 35.4% WHO | 93% WHO |
| 2020 | 36.2% WHO | 81% WHO |
| 2021 | 37% WHO | 69% WHO |
| 2022 | 37.8% WHO | 75% WHO |
| 2023 | 38.6% WHO | 83% WHO |
| 2024 | 39.4% WHO | 87% WHO |
Provenance
Where these numbers come from
Adult obesity prevalence: female (age-standardized, %)
Percentage of female adults aged 18 and older with a body mass index (BMI) of 30 kg/m² or higher, age-standardized estimate.
30 observations charted in Costa Rica · source organisations: WHO
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%)
The percentage of children who have received two doses of measles-containing vaccine (MCV2) in a given year, according to the nationally recommended schedule, based on WHO/UNICEF Estimates of National Immunization Coverage (WUENIC).
26 observations charted in Costa Rica · source organisations: WHO
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring